Clinical trial · Observational
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
Plasma Expression Levels of MicroRNA-21 Might Help for Detection of HCV Patients Complicated by Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis C | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Complicated HCV
- interventionNames
- Biological: Blood Sampling
- label
- Non Complicated HCV
- interventionNames
- Biological: Blood Sampling
Primary outcomes (1)
- measure
- Relation between MicroRNA and HCV
- timeFrame
- 12 months
- description
- The ability of estimation of plasma microRNA 21 and 126 to differentiate between uncomplicated and complicated HCV patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 31 Years
- Maximum age
- 67 Years
Show eligibility criteria text
Inclusion Criteria: * Complicated hepatitis C by HCC * Complicated hepatitis C by liver cirrhosis * Complicated hepatitis C by steatohepatitis * uncomplicated hepatitis C Exclusion Criteria: * pre-portal fibrosis secondary to previous bilharzial disease * pre-portal fibrosis secondary to alcoholic fatty liver * The presence of hepatic malignancy other than HCC * decompensated cirrhosis * hepatorenal failure * hepatic manifestations of congestive heart failure.
References
Publications (0)
Data not yet available